Exp Hematol:急性髓系白血病化疗损伤后免疫成分及其与血液学恢复的关系

2021-11-28 MedSci原创 MedSci原创

化疗后 BM 中的 NK/CD4CM 比率与随后中性粒细胞恢复的时间显着相关(Spearman's ρ = -0.723,p < 0.001,FDR < 0.01)。

化疗引起的骨髓 (BM) 损伤是急性髓系白血病 (AML) 发病率和死亡率的重要原因。为了在化疗损伤后实现血液学恢复,BM 中残留的正常造血干/祖细胞 (HSPC) 需要补充成熟的血细胞。HSPC 行为受到其微环境(即所谓的 HSPC 生态位)的严格调控。许多研究中的发现意味着淋巴细胞亚群可能在 AML 化疗后的造血恢复中发挥作用,但淋巴细胞亚群如何受到强化化疗的影响仍然未知。在这里,国外研究团队评估了评估了先天和适应性免疫子集组成的再生BM诱导化疗后(17天)及相关血液AML的复苏,并将其与 AML 的血液学恢复相关联。
 
 
研究人员在开始缓解诱导化疗(7+3 方案的阿糖胞苷和蒽环类化疗)后 17 天(范围 16-19)收集 AML 患者(平均:58 岁,范围:20-75 岁)的 BM 抽吸物。在获得书面知情同意后,通过同种异体移植捐赠者的抽吸获得对照骨髓(平均:64.8 岁,范围:47-78 岁)。伊拉斯谟医学中心(荷兰)机构审查委员会根据赫尔辛基宣言批准在知情同意的情况下使用人体样本。
 
从 BM 抽吸物中分离出单核细胞 (MNC)。随后,BM 抽吸物进行离心并用 PBS+0.5% FCS 洗涤一次。接下来,BM 抽吸物被分成两部分,并用以下两种抗体混合物中的一种染色:一种混合物 (1) 确定单核细胞、B 细胞、T 细胞、NK 细胞、B 细胞的频率,另一种混合物 (2) ) 以确定初始和记忆 T 细胞亚群的频率。对于 (1),使用 CD14和包含 CD45、CD3、CD16/CD56 和 CD19 的多测试混合物,而对于 (2),使用CD45 , CD45RA , CD3 , CD4 、CD8和 CD62L。
 
 
图 1 :AML 强化化疗后恢复后 BM 免疫亚群的组成
图 2: CD4CM T 和 NK 细胞的频率与 AML 化疗后中性粒细胞的恢复有关。
 
结果显示,T 细胞,特别是 CD4 中央记忆 (CD4CM) T 细胞亚群,在化疗后在 BM 中显着富集,表明细胞的相对化学抗性为全身病原体提供长期记忆。相比之下,B 细胞和其他造血亚群被耗尽。CD4CM T 细胞亚群的较高频率与造血恢复延迟有关,而 NK 细胞的较高频率与中性粒细胞计数的较快恢复有关。
 
研究表明,化疗后 BM 中的 NK/CD4CM 比率与随后中性粒细胞恢复的时间显着相关(Spearman's ρ = -0.723,p < 0.001,FDR < 0.01)。这些数据为化疗损伤后的免疫重建提供了新的见解,并暗示 CD4CM 和 NK 细胞之间的平衡是 AML 造血恢复的潜在预测因素。预计这些发现将促使未来对特定免疫亚群在 HSPC 恢复中的作用进行调查,并指导未来支持治疗的潜在定制。
 
原始出处:
Kenswil KJG,Pisterzi P,Feyen J,et al.Immune composition and its association with hematologic recovery after chemotherapeutic injury in acute myeloid leukemia.[J].Exp Hematol,1970,:.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1207977, encodeId=89f1120e97795, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9af96571446, createdName=ms7000001055015876, createdTime=Fri Apr 01 22:28:14 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822118, encodeId=e234182211859, content=<a href='/topic/show?id=ee4b1021266e' target=_blank style='color:#2F92EE;'>#髓系白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102126, encryptionId=ee4b1021266e, topicName=髓系白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Sat Jun 11 16:13:39 CST 2022, time=2022-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317673, encodeId=4b0a131e67360, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Tue Nov 30 06:13:39 CST 2021, time=2021-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1398238, encodeId=3ebb139823872, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Tue Nov 30 06:13:39 CST 2021, time=2021-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466328, encodeId=a4a914663284e, content=<a href='/topic/show?id=765c8925904' target=_blank style='color:#2F92EE;'>#血液学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89259, encryptionId=765c8925904, topicName=血液学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=67c86798320, createdName=hxq78318, createdTime=Tue Nov 30 06:13:39 CST 2021, time=2021-11-30, status=1, ipAttribution=)]
    2022-04-01 ms7000001055015876

    学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1207977, encodeId=89f1120e97795, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9af96571446, createdName=ms7000001055015876, createdTime=Fri Apr 01 22:28:14 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822118, encodeId=e234182211859, content=<a href='/topic/show?id=ee4b1021266e' target=_blank style='color:#2F92EE;'>#髓系白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102126, encryptionId=ee4b1021266e, topicName=髓系白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Sat Jun 11 16:13:39 CST 2022, time=2022-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317673, encodeId=4b0a131e67360, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Tue Nov 30 06:13:39 CST 2021, time=2021-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1398238, encodeId=3ebb139823872, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Tue Nov 30 06:13:39 CST 2021, time=2021-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466328, encodeId=a4a914663284e, content=<a href='/topic/show?id=765c8925904' target=_blank style='color:#2F92EE;'>#血液学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89259, encryptionId=765c8925904, topicName=血液学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=67c86798320, createdName=hxq78318, createdTime=Tue Nov 30 06:13:39 CST 2021, time=2021-11-30, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1207977, encodeId=89f1120e97795, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9af96571446, createdName=ms7000001055015876, createdTime=Fri Apr 01 22:28:14 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822118, encodeId=e234182211859, content=<a href='/topic/show?id=ee4b1021266e' target=_blank style='color:#2F92EE;'>#髓系白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102126, encryptionId=ee4b1021266e, topicName=髓系白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Sat Jun 11 16:13:39 CST 2022, time=2022-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317673, encodeId=4b0a131e67360, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Tue Nov 30 06:13:39 CST 2021, time=2021-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1398238, encodeId=3ebb139823872, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Tue Nov 30 06:13:39 CST 2021, time=2021-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466328, encodeId=a4a914663284e, content=<a href='/topic/show?id=765c8925904' target=_blank style='color:#2F92EE;'>#血液学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89259, encryptionId=765c8925904, topicName=血液学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=67c86798320, createdName=hxq78318, createdTime=Tue Nov 30 06:13:39 CST 2021, time=2021-11-30, status=1, ipAttribution=)]
    2021-11-30 fengyi812
  4. [GetPortalCommentsPageByObjectIdResponse(id=1207977, encodeId=89f1120e97795, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9af96571446, createdName=ms7000001055015876, createdTime=Fri Apr 01 22:28:14 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822118, encodeId=e234182211859, content=<a href='/topic/show?id=ee4b1021266e' target=_blank style='color:#2F92EE;'>#髓系白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102126, encryptionId=ee4b1021266e, topicName=髓系白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Sat Jun 11 16:13:39 CST 2022, time=2022-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317673, encodeId=4b0a131e67360, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Tue Nov 30 06:13:39 CST 2021, time=2021-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1398238, encodeId=3ebb139823872, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Tue Nov 30 06:13:39 CST 2021, time=2021-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466328, encodeId=a4a914663284e, content=<a href='/topic/show?id=765c8925904' target=_blank style='color:#2F92EE;'>#血液学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89259, encryptionId=765c8925904, topicName=血液学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=67c86798320, createdName=hxq78318, createdTime=Tue Nov 30 06:13:39 CST 2021, time=2021-11-30, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1207977, encodeId=89f1120e97795, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9af96571446, createdName=ms7000001055015876, createdTime=Fri Apr 01 22:28:14 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822118, encodeId=e234182211859, content=<a href='/topic/show?id=ee4b1021266e' target=_blank style='color:#2F92EE;'>#髓系白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102126, encryptionId=ee4b1021266e, topicName=髓系白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Sat Jun 11 16:13:39 CST 2022, time=2022-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317673, encodeId=4b0a131e67360, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Tue Nov 30 06:13:39 CST 2021, time=2021-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1398238, encodeId=3ebb139823872, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Tue Nov 30 06:13:39 CST 2021, time=2021-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466328, encodeId=a4a914663284e, content=<a href='/topic/show?id=765c8925904' target=_blank style='color:#2F92EE;'>#血液学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89259, encryptionId=765c8925904, topicName=血液学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=67c86798320, createdName=hxq78318, createdTime=Tue Nov 30 06:13:39 CST 2021, time=2021-11-30, status=1, ipAttribution=)]

相关资讯

Clin Cancer Res:曲妥珠单抗联合内分泌或化疗作为HR+HER2+转移性乳腺癌的一线治疗的疗效对比

曲妥珠单抗联合内分泌治疗作为激素受体阳性、HER2阳性的转移性乳腺癌的一线方案的效果不劣于曲妥珠单抗联合化疗

JCO:派姆单抗 vs 化疗作为二线疗法对晚期食道癌患者生活质量的影响

CPS≥10分的食道鳞状细胞癌患者采用派姆单抗单药或化疗维持治疗的健康相关生活质量无明显差异

J Clin Oncol:乳腺癌化疗后大脑认知功能减退的罪魁祸首

化疗脑:20%~40%的乳腺癌患者化疗后可出现记忆力、注意力、思维等大脑认知功能减退,可能持续至康复期并干扰日常生活技能和生活质量。在化疗前预测化疗后有脑功能减退风险的乳腺癌患者,将有助于改善患者治疗

Front Oncol: 化疗对I期鼻咽癌患者的预后影响

研究表明,在放疗的基础上添加化疗并不能改善I期鼻咽癌患者的预后。放疗仍是该类患者的推荐治疗手段。

ESMO Open:接or不接?对于抗癌治疗患者,BNT162b2 COVID-19疫苗效果如何?

抗肿瘤治疗患者对BNT162b2新冠mRNA疫苗的体液免疫反应降低,尤其是接受化疗或利妥昔单抗的患者。

Eur Urol:转移去势抵抗性前列腺癌中,激素治疗与化疗获益的预测性基因组生物标志物调查

新的激素疗法(NHTs),如阿比特龙和恩扎鲁胺,以及基于紫杉类药物的化疗,是治疗转移去势抵抗性前列腺癌(mCRPC)的常用系统疗法。

拓展阅读

Lancet Haematol:小剂量阿扎胞苷加venetoclax作为急性髓系白血病强化或低强度诱导后的维持治疗

研究也首次证明了在强化诱导后,低剂量氮杂胞苷加venetoclax治疗急性髓系白血病是一种可行且安全的维持治疗策略。

【今日分享】CACA 成人急性髓系白血病整体综合管理指南

CACA 成人急性髓系白血病关注年轻和老年患者,同时关注AML并发症的治疗以及AML患者的护理从整体整合医学的角度来提升生活质量和治疗效果。血液科医生别错过!

指南解读 | 急性髓系白血病NCCN(2024):进一步细化患者分层和治疗方案,促进诊疗个体化和精准化!

《急性髓系白血病NCCN临床实践指南》目前已更新至2024.V2,与上一年终版2023.V6相比有较多变化,本文将对药物治疗相关更新内容进行解读,供各位医学同仁参考。

Int J Clin Oncol:急性髓系白血病诱导治疗后G-CSF初级预防的有效性和安全性

对于接受缓解诱导治疗且感染性并发症风险较高的成人AML患者,可以考虑使用G-CSF作为一级预防。

【JCO】FLT3-ITD AML移植后基于MRD的吉瑞替尼维持治疗,助力整体治疗策略

学者使用 FLT3 抑制剂吉瑞替尼开展一项 HCT 后维持治疗的随机研究,以确定所有此类患者是否均获益,以及MRD是否可以确定哪些患者获益。

【AJH】细胞遗传学异常中仅复杂核型是NPM1突变AML移植后不良预后因素

学者通过欧洲血液和骨髓移植学会 (EBMT) 登记组,研究了伴CG 异常的NPM1 突变 AML在CR1 接受 alloHSCT 的情况。

CACA 成人急性髓系白血病整体综合管理指南

中国抗癌协会(CACA,Chinese Anti-cancer Association) · 2024-03-14

成人急性髓系白血病(非急性早幼粒细胞白血病)中国诊疗指南(2023年版)

中华医学会血液学分会白血病淋巴瘤学组 · 2024-01-01

中国复发难治性急性髓系白血病诊疗指南(2023年版)

中华医学会血液学分会白血病淋巴瘤学组 · 2024-01-01

FDA指导文件:急性髓系白血病开发用于治疗的药物和生物制品

美国食品和药品监督管理局(FDA,Food and Drug Administration) · 2022-10-17

WHO 2022第5版急性髓系白血病分类解读

浙江大学医学院附属第一医院血液科 · 2023-03-01

急性髓系白血病新药临床研发技术指导原则

国家药品监督管理局药品审评中心(CDE) · 2023-02-13